EFFECT OF OIL IN WATER AND ALUM ADJUVANTS ON THE POTENCY OF RECEPTOR BINDING DOMAIN BASED COVID-19 SUBUNIT VACCINE

Along with the spread of COVID-19 in various parts of the world, many parties are researching to create a vaccine to control the disease. They continue researching the COVID-19 vaccine according to the World Health Organization (WHO) recommendations. The use of adjuvants greatly affects the pot...

Full description

Saved in:
Bibliographic Details
Main Author: Purnama, Irpan
Format: Theses
Language:Indonesia
Online Access:https://digilib.itb.ac.id/gdl/view/73963
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Institut Teknologi Bandung
Language: Indonesia
Description
Summary:Along with the spread of COVID-19 in various parts of the world, many parties are researching to create a vaccine to control the disease. They continue researching the COVID-19 vaccine according to the World Health Organization (WHO) recommendations. The use of adjuvants greatly affects the potential value of vaccines, especially subunit vaccines. Another challenge in vaccine development is the cost of the vaccine, especially in developing countries like Indonesia. This study was conducted to determine the effect of differences in oil in water (OIW) adjuvants and aluminum adjuvants on the immune response along with the resulting cost analysis using non-inferiority studies and cost analysis of the use of adjuvants compared to the RBD vaccine, which already has a distribution permit in Indonesia (RBD- CPGs/Alums). In this study, OIW was made independently using a microfluidizer and AlPO4 with the stirring method, while Al(OH)3 was used directly from the vendor. Formulations were made with various RBD ratios with adjuvants. Potency was measured using ELISA against the serum of Bulb c mice immunized via the intramuscular route twice. For statistical analysis, one-way ANOVA and Geometric Mean Titer (GMT) were used to determine the best ratio of RBD and adjuvant. Analysis of the cost ratio of RBD and the best adjuvant compared to RBD vaccines that already have distribution permits. The study showed that RBD 25 µg and 50 µg, formulated with OIW adjuvants, had the best immune response. The use of OIW adjuvants costs 15 times lower than similar vaccines in circulation. The formulation produced in this study has the potential to be developed on a larger scale production.